GeneSys Biologics Revenue and Competitors
Estimated Revenue & Valuation
- GeneSys Biologics's estimated annual revenue is currently $20.5M per year.
- GeneSys Biologics's estimated revenue per employee is $114,302
Employee Data
- GeneSys Biologics has 179 Employees.
- GeneSys Biologics grew their employee count by -17% last year.
GeneSys Biologics's People
Name | Title | Email/Phone |
---|---|---|
1 | Head Quality Control, Biologics - General Manager | Reveal Email/Phone |
2 | Assistant General Manager (Head-Analytical Development and Characterisation) | Reveal Email/Phone |
3 | Senior Manager | Reveal Email/Phone |
4 | Deputy General Manager and Head RND- Drug Substance & MSAT | Reveal Email/Phone |
5 | Deputy Manager -Manufacturing QMS | Reveal Email/Phone |
6 | Quality Control Manager | Reveal Email/Phone |
7 | Deputy General Manager | Reveal Email/Phone |
8 | General Manager | Reveal Email/Phone |
9 | Assistant Manager | Reveal Email/Phone |
10 | Executive | Reveal Email/Phone |
GeneSys Biologics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $12M | 122 | -4% | N/A | N/A |
#2 | $17.3M | 223 | 18% | N/A | N/A |
#3 | $11.1M | 143 | 34% | N/A | N/A |
#4 | $8.2M | 143 | 64% | N/A | N/A |
#5 | $9.5M | 121 | 20% | N/A | N/A |
#6 | $21.2M | 246 | 10% | N/A | N/A |
#7 | $12M | 155 | 8% | N/A | N/A |
#8 | $18.9M | 248 | 24% | N/A | N/A |
#9 | $12.5M | 163 | 23% | N/A | N/A |
#10 | $20.5M | 179 | -17% | N/A | N/A |
What Is GeneSys Biologics?
GeneSys Biologics was established in Nov 2014 by a group of like-minded individuals with strong global experience in development of biosimilars. A science-based biosimilar company with the vision of becoming one of the leading global biopharmaceutical companies in the world. GeneSys aims to expand market access across the globe by providing affordable and high quality biosimilars.
keywords:N/AN/A
Total Funding
179
Number of Employees
$20.5M
Revenue (est)
-17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
GeneSys Biologics News
2022-03-22 - Insulin has been around for 100 years, so why is it still so ...
... with GeneSys Biologics to develop and commercialize three biosimilar versions of insulins in the U.S.glargine, lispro and aspart.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $14.4M | 180 | 6% | N/A |
#2 | N/A | 182 | 29% | N/A |
#3 | $27.2M | 183 | 3% | N/A |
#4 | $41.9M | 183 | 6% | N/A |
#5 | $4.8M | 184 | 124% | N/A |